THE EFFECTIVENESS OF THE DRUG KENTRON IN SEVERE FORMS OF NEUROPATHY OF THE FACIAL NERVE

Abstract

Objective: Assessment of the effectiveness of the drug Kentron in severe forms of facial neuropathy. Material and
methods: 52 (100%) patients with severe degrees of IOL were included in the study. Of these, 32 (61.5%) received
standard therapy with the addition of a drug with the metabolic effect of Kentron 5.0 ml IM once a day for 10 days
(main group), 20 (38.4%) patients of the comparison group received standard therapy, including angioprotectors,
anti-inflammatory drugs that improve blood rheology, physiotherapy and physiotherapy. Results: Kentron improves
conduction along the motor fibers of the facial nerve, affects nerve fibers modified by the pathological process, which
is also confirmed by the clinical picture. The use of Kentron in the complex treatment of facial neuropathy can improve
results, achieve a pronounced decrease in paresis of the facial muscles, and in the acute stage, complete restoration of
the movements of the facial muscles in a short time. When appointing Kentron, we did not observe the development of
contractures. Conclusions: Kentron is an effective drug for the treatment of facial neuropathy, regardless of the duration
of the disease and the start of treatment. The effectiveness of the drug increased with early administration and
was determined by a decrease in the time of full recovery to 7-10 days.